Strategic Licensing Opportunity Lytix’s ongoing license with Verrica for non-melanoma skin cancers demonstrates a validated collaboration model and creates a pathway to broaden the oncolytic peptide platform through additional territories and potential co-development or new indications with corporate partners.

Dermatology Commercial Path With a focus on non-melanoma skin cancers such as basal cell and squamous cell carcinoma and supportive data from Verrica, there are near term opportunities to partner with dermatology clinics, payers, and regional distributors to accelerate early adoption.

Immunotherapy Synergy Ruxotemitide is designed to work in synergy with immune checkpoint inhibitors and to overcome resistance, positioning it as a compelling add on or combination therapy for IO programs and patients who have progressed on prior therapies.

Global BD Momentum Global business development momentum is aided by a world class advisory network, leadership additions, and a strategy to engage in co development and licensing of pipeline assets beyond current territories.

Partnership Opportunities Credible validation from industry forums, the Verrica licensing deal, and a pipeline with deep-tissue targets offer multiple entry points for milestone driven collaborations, manufacturing partnerships, and strategic deals.